Neurocrine Biosciences Inc. Message Board
-
Is NBIX going to be a 2013
M&A Target??????????
IMO,,,,,,, If UF P2 trials positive for E .. Abbott will take NBIX out for a nice premo price.
Given Abbotts worldwide Womens health drug franchise its a no brainer.
Give Kevy and the boys a nice pay day to play some serious Golf.
frogs-
Endo phase 2's were already positive. You must be thinking about uterine fibroids?
- 1 Reply to investormdpart2
-
just for clarity
E - Elagolix
UF = Uterine Fibroids
-
Abbott is going CANADIAN with a small but sizzling company calles APRI with
an impressive list of medical novelties, the first FDA approved is also on the verge of
getting the Canadian Govt approval.
Heavyweight ABBOTT has made here a major pharmaceutical deal.
It has signed (earley 2012) to become the official drug house to start a full introduction of APRI's
novel drugs in Canada.A very clear indication of ABT's plans with APRI and Canada.
It was developed by Apri on the premise that leading
sex psychiatrists claim is the key to a truly satisfying sexual and personal bondage.
This ASPRI drug should make 30% - 40% of women
who at the moment cannot enjoy sex in marriage/friendship relations due to the
constant lingering of these psychic side effects. The make believe that these women
adopt always break down,causing tensions to get out of hand.
This seems to be the major cause of this high percentige
of women to need treatment.
Children of these women are also likely to be affected- when time comes
to go find a husband, she will also get good to
make believe her passion is genuine.
ABT has done their home work as usual.
Apri has already started to negotiate with some of the larger
European and Far Eastern Pharma Houses on taking this drug to market.
Some deals have been made recently.
At $ 2.00 APRI look inexpensive.
Good luck to all .
LarsSentiment: Strong Buy
- 1 Reply to b_lwa
-
I'm in APRI but it has been a terrible investment so far. The CEO was booted or quit, the drug Abbott is partnered on is delayed to market with no updates on launch timing and their focus is changing all the time. Now they don't even mention the specialty oncology products they spent so much on. Personally, I'd like to see someone buy that hunk of junk and set me free! Terrible terrible investment so far. My only hope is that someone buys them.
-